At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 87 enrolled
Drug / intervention
VX-121 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis
In Brief
A Phase 2 clinical trial evaluating VX-121, TEZ, and 4 other interventions for Cystic Fibrosis. Completed, enrolled 87 participants across 26 sites in 5 countries.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of VX-121 combination therapy in subjects with cystic fibrosis (CF).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesGermany, Netherlands, Portugal, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartApr 2019
Primary CompletionDec 2019
TodayJul 2026
First PostedApr 11, 2019
Enrollment StartApr 30, 2019
Primary CompletionDec 10, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.2 years ago
Interventions
VX-121drug
Tablets for oral administration.
TEZdrug
TEZ tablet for oral administration.
VX-561drug
Tablets for oral administration.
TEZ/IVAdrug
Fixed-dose combination tablets for oral administration.
IVAdrug
Tablets for oral administration.
Placebodrug
Placebos matched to VX-121, TEZ, and VX-561 for oral administration.